About Allomedin
ALLOMEDIN® is an innovative dermatological agent containing a unique synthetic peptide Allostatin®-1, designed to protect the skin and mucous membranes from the manifestations of viral infections that cause inflammatory processes and neoplasms of epithelial tissues. ALLOMEDIN® is an innovative drug with a unique mechanism of action! It detects cells infected by the viruses, actives recognition of these cells by the immune system which enables the NK and T cells to destroy the cells infected by the virus. It works with all almost all RND and DNA type of viruses.
Clinical Study in Italy
A joint clinical study was carried out in IRCCS Policlinico San Martino Genova, Italy on the Immunomodulatory potential, and clinical efficacy of Allostatine against Type 1 and 2 Herpes Simplex Virus (HSV) lesions. The following institutions participated in this clinical study:
- IRCCS Policlinico San Martino Genova, Italy
- 2 Unit of Bioactive Natural Substances and Biotechnology UR17ES47, Faculty of Dental Medicine of Monastir, University of Monastir, Avicenne Street, 5000 Monastir, Tunisia
- Laboratory of Insect Biopharmacology and Immunology, Faculty of Biology, St. Petersburg State University, Russia
- Department CHIBIOFARAM, University of Messina, Messina, Italy.
- Department of Experimental Medicine, School of Medicine; University of Genoa, Italy
- Epitopoietic Research Corporation (ERC), Landerd campus, Nistelrooisebaan 3, 5374 RE Schaijk, The Netherlands
- Cell Biology and Immunology, Wageningen, University, The Netherlands. (The Netherlands).
Inclusion criteria
In a first study, patients of both sexes, ranging from18-60 years of age, with a medical diagnosis of recurrent (>3 relapses in the past 4 years) herpes simplex lesions, clinically and in laboratory confirmed, were selected for the study. For the second clinical evaluation, 156 patients aged from 18 to 80 years old, 80 men and 76 women, were selected. These patients were clinically diagnosed with chronic recurrent herpes simplex.
Conclusion
According to our clinical data, Allostatine and it gel formulation Allomedin, demonstrate excellent therapeutic efficacy and safety as a therapy for skin and mucous tunic HSV1 and HSV2 infections. In fact, the clinical data from the present study confirm that 90 to 95% of colds sores and genital herpes cases can be effectively controlled by Allomedin treatment. To the best of our knowledge, there is no other drug or cosmeceutical that is currently as effective as Allomedin for this indication. Nowadays about 90% of the human population is infected with HSV. HSV causes lifelong infections manifesting in different forms varying from mild disorders (cold sores) to severe chronic forms such as relapsing genital herpes. According to European STD guidelines approved by the WHO [Patel et al., 2017], a group of drugs is 29 recommended for systemic administration (per os or iv) since their topical formulations have very limited efficacy. We demonstrated that Allomedin eliminates most of the unpalatable sympoms of HSV infections such as itch, burning, oedema, much faster than acyclovir. Worthy to note is that long term treatment with acyclovir give rise to acyclovir resistant strains that, obviously, worsen herpes therapy perspectives. Since the Allostatine mode of action is completely different from that of acyclovir, Allomedin can be effectively used against acyclovir resistant HSV as well.
Read More:
Clinical Studies in Russia
The Allomedin therapeutic efficacy and safety have been clinically evaluated in the following specialized hospitals and medical centers in Russia
- Russian medical academy of postgraduate education, St. Petersburg (dermatology and cosmetology department, stomatology department)
- Petersburg city center for prevention of infectious diseases
- Pasteur research institute, St. Petersburg
- Center for preventive Medicine, St. Petersburg
- Center of clinical immunology, St. Petersburg
- Republican clinical hospital for infectious diseases
- First St. Petersburg medical university (department of otorhinolaryngology)
- District antenatal clinic №1, St. Petersburg
- District antenatal clinic №2, St. Petersburg
- Medical university, Petrozavodsk
Inclusion:
A total of 168 patients with herpes and 272 patients with HPV are included in this clinical study
Conclusion:
All 10 clinical studies concluded that the long term preclinical and clinical studies demonstrated extraordinary therapeutic efficacy of Allomedin in the therapy of skin and mucous tunic HSV and HPV infections. To our best knowledge there is no drug or cosmeceutical that could be as effective as Allomedin in this field for the time being.